Atyr Pharma Inc. (NASDAQ:LIFE) saw strong trading volume on Friday . 561,733 shares traded hands during mid-day trading, an increase of 137% from the previous session’s volume of 236,978 shares.The stock last traded at $3.18 and had previously closed at $2.97.

Several research analysts recently weighed in on the company. Zacks Investment Research upgraded Atyr Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 24th. BMO Capital Markets reiterated a “hold” rating on shares of Atyr Pharma in a research report on Thursday, May 12th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $23.75.

The firm has a 50-day moving average of $2.85 and a 200 day moving average of $3.96. The firm’s market capitalization is $80.77 million.

Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.02. Equities research analysts anticipate that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In related news, insider Grove Matsuoka purchased 12,412 shares of Atyr Pharma stock in a transaction dated Wednesday, May 11th. The stock was bought at an average cost of $3.04 per share, for a total transaction of $37,732.48. Following the transaction, the insider now owns 2,412 shares in the company, valued at $7,332.48. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.